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doi:10.1016/j.jmii.2012.04.004Background: There is limited information about pneumococcal carriage among healthy chil-
dren in Malaysia. Therefore, this study was conducted to determine the prevalence rate, sero-
type distribution, susceptibility pattern, and pneumococcal surface protein A (PspA) family
types of Streptococcus pneumoniae isolates in the nasal carriage of children 5 years old or
younger in three day care centers in Kuala Lumpur, Malaysia.
Methods: Nasal swabs were collected from 195 healthy children, age 5 years or younger, from
June to December 2010. S pneumoniae was identified by phenotypic and genotypic methods.
The serotyping was performed using Pneumotest kit (Statens Serum Institut, Copenhagen,
Denmark) and the susceptibility pattern was determined by using the E-test method (AB Bio-
disk, Solna, Sweden). PspA family typing was done using polymerase chain reaction.
Results: S pneumoniae was found in the nasal carriage of 35.4% of children (69 of 195) and
penicillin resistance was found in 23.2% (16 of 69). Among the 69 isolates, multidrug-
resistant S pneumoniae (MDRSP) was present in 20.3%. All 16 penicillin-resistant S pneumoniae
(PRSP) isolates were resistant to erythromycin and 14 PRSPs (87.5%) were resistant to co-tri-
moxazole. The six most common serotypes were 6A, 23F, 19A, 6B, 19F, and 15C, which were
found in 87% of all isolates. Of the 69 isolates, 24.6% belonged to PspA family 1, 71.0% to PspA
family 2, and 4.3% to PspA family 3.
Conclusion: Twenty-eight of the isolates (40.6%) belonged to serotypes included in the pneu-
mococcal polysaccharide vaccines (PCV) 7 and 10, whereas 48 (69.5%) were included in
PCV13. The high rate of PRSP and MDRSP supports the need for continuing surveillance ofof Medical Microbiology and Parasitology, Faculty of Medicine and Health Sciences, Universiti Putra
.upm.edu.my (S.N. Masri).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Determination of phenotypes and pneumococcal surface protein A 181pneumococcal carriage. The major PspA families were 1 and 2 (95.7%), thus making them suit-
able candidates for future vaccines.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Streptococcus pneumoniae is a major agent for respiratory
and invasive disease worldwide, particularly in children
younger than 5 years, elderly persons, and immunocom-
promised individuals.1 In many cases, pneumococcal
diseases are preceded by nasopharyngeal colonization.
Crowded day care centers facilitate the spread of pneu-
mococcal diseases. Many studies have shown that the
highest frequency of pneumococcal colonization is found in
young children, and this group might be the most important
vector for horizontal spread of pneumococcal strains within
the community.2 The efficacy of penicillins and other
antibiotics has been dramatically reduced recently because
of an increasing rate of resistance and rapid spread of
multidrug-resistant strains.3,4
Currently, immunization is the ideal way to prevent
pneumococcal disease. There are two types of licensed
vaccines: pneumococcal polysaccharide vaccine (PPV) and
pneumococcal conjugate vaccine (PCV). Although the 23-
valent PPV is protective in children older than 2 years, this
vaccine fails to protect children younger than 2 years
because of its inability to elicit immunologic memory.5 To
induce immunogenicity, several PCVs such as PCV7, PCV10,
and PCV13 are produced to provide protection, especially
in children 2 years old and younger.6 However, its cost
limits the use of PCV in developing countries. Also, it has
been shown that vaccine serotypes are now being replaced
by nonvaccine serotypes as causes of disease.7,8 To date,
there are no data to support the premise that serotype
replacement has occurred in Malaysia. Although the use of
vaccine serotypes is a positive step toward prevention,
efforts are under way to produce more effective vaccines.
Pneumococcal virulence proteins, which are found in all
disease-causing strains, are currently the focus of vaccine
development.9 Several virulence proteins, including pneu-
molysin (ply), autolysin (lytA), pneumococcal surface
protein A (PspA), pneumococcal surface protein C (PspC),
and neuraminidase A (NanA), are being studied.9,10 PspA is
among the most studied and highly promising virulence
proteins because it is highly immunogenic and expressed
virtually by all pneumococci.11,12 PspA is composed of three
structural domains: the N-terminal region, C-terminal
choline binding region, and proline-rich region. Based on
sequences of the N-terminal region, which is composed of
repeated alpha-helices and is highly polymorphic, it can be
grouped into three families and can be subdivided into six
clades, with most pneumococcal strains belonging to family
1 and family 2.13e15 The family can be determined by
polymerase chain reaction (PCR) and the clades are
identified by sequencing.13 This study was conducted to
determine the prevalence rate of S pneumoniae, serotype
distribution, and susceptibility pattern of S pneumoniaeisolated from healthy children in three day care centers in
Malaysia. The distribution of PspA family type and its
relationship with serotype distribution and penicillin
susceptibility were also investigated.Materials and methods
Study design
A cross-sectional descriptive study was carried out. Samples
were obtained from children age 5 years and younger who
attended three day care centers in Kuala Lumpur, Malaysia
from June to December 2010. This study was approved by
the Universiti Putra Malaysia (UPM) Medical Research Ethics
Committee.Study population
All healthy children 5 years old and younger who attended
three day care centers were eligible to participate in this
study; those who were recently hospitalized or receiving
antibiotic treatment were excluded. Written informed
consent was obtained from the parent or guardian.Sample collection
A nasal sample from both sides of the anterior nares was
obtained from each child using a cotton-tipped swab. A
nasal swab was used because it is much easier to perform
without sacrificing the sensitivity of detection of pneumo-
coccal carriage.16 The swabs were placed into Amies
transport media and transferred to the laboratory at room
temperature. Within 3 to 4 hours of sample collection, the
swabs were cultured onto sheep blood agar and incubated
overnight at 35 C in 5% CO2.Identification of isolates
Pneumococcal isolates were identified based on colonial
morphology, Gram staining, catalase test, bile solubility,
and susceptibility to ethylhydrocupreine hydrochloride
(optochin).17 The identity of S pneumoniae was also
confirmed using PCR for detection of ply and lytA genes.Serotyping
Serotyping was performed by latex agglutination using
Pneumotest kit commercial antisera18 (Statens Serum
Institut, Copenhagen, Denmark).
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Susceptibility of pneumococcal isolates to penicillin,
erythromycin, co-trimoxazole, cefotaxime, ceftriaxone,
and amoxicillin/clavulanic acid was determined based on
the minimum inhibitory concentration (MIC) using the E-
test method (AB Biodisk, Solna, Sweden). The test was
performed using the methodology recommended by the
Clinical and Laboratory Standards Institute (CLSI) guide-
lines.19 S pneumoniae ATCC 49619 was used as the control
strain. The MIC results were compared to CLSI interpretive
criteria and interpreted as susceptible (S), intermediate (I),
or resistant (R). Multidrug-resistant S pneumoniae (MDRSP)
is defined as resistance to more than two different classes
of antibiotics.20
DNA extraction and purification
DNA was extracted using the GeneAll Exgene kit and
purification was done using the GeneAll Expin PCR SV
Protocol Handbook (GeneAll Biotechnology Co. Ltd, Seoul,
Korea) in accordance with the instructions provided by the
manufacturer.
PCR detection of pneumolysin (ply) and autolysin
(lytA) genes and PspA family typing
The presence of ply gene, lytA gene, and PspA family
typing were determined by using the primers listed in
Table 1.12e14,21,22
Amplification was carried out in a total volume of 25 mL
containing 0.5 mM each primer, 30 mM each dNTP, 1.5 mM
MgCl2, 1 U Taq DNA polymerase, and 1-10 ng DNA template.
S pneumoniae ATCC 49619 was used as a positive control
sample. A negative control sample containing the same
reaction mixture except the DNA template was included in
every experiment. All PCR amplifications were perfomed
using a thermal cycler (BioRad MyCyclerTM Themalcycler,
USA). Initial denaturation was at 94 C for 5 minutes, fol-
lowed by 30 cycles of denaturation at 94 for 30 seconds,
annealing at 55 C for 30 seconds and extension at 72 C for
30 seconds. Finally, an additional extension was set for 10
minutes at 72 C. The amplification conditions for the plyTable 1 Oligonucleotide primers used in this study
Primer Primer sequence (50 - 30)
Pneumolysin (ply) Forward ATTTCTGTAACAGCTACCAACG
Reverse GAATTCCCTGTCTTTTCAAAGT









SKH2 CCACATACCGTTTTCTTGTTTCCAGCCand lytA gene fragments were similar except for the
annealing temperature (Table 1). Three mL of amplicon of
each PCR product was electrophoresed on a 1.2% agarose
gel for 1 hour at 85 V, visualized and photographed under
UV illumination with a 100-bp DNA ladder as a molecular
weight marker. Representatives of the 348-bp product of
ply gene and 319 bp of lytA gene were sequenced at First
Base Laboratories (Seri Kembangan, Malaysia), and
compared in the GenBank database for gene confirmation.
The classifications of PspA family were determined by
using primers for family 1 (LSM12/SKH63), family 2 (LSM12/
SKH52), and family 3 (SKH41/SKH42) as listed in Table 1.
PCRs were carried out in a standard mixture of 25 mL
containing 0.5 mM each primer, 30 mM each dNTP, 1.5 mM
MgCl2, 1 U Taq DNA polymerase, and 1-10 ng DNA
template. Cycling conditions were as follows: 95 C (3
minutes); 30 cycles of 95 C (1 minute), 62 C (1 minute),
72 C (3 minutes), and 72 C for 10 minutes. PCR amplicon
products were electrophoresed on a 1.0% agarose gel (40
minutes) at 90 V, visualized and photographed under UV
illumination with a 1-kb DNA ladder as a molecular weight
marker. PCR product for family 1 is approximately 1000 bp
and 1200 bp for family 2. LSM12/SKH2 primer was used to
amplify any PspA family from all strains. The results were
recorded as nontypeable when the PspA family was not
determined after three attempts.12e14 The PCR products
from each of the three families were purified and
sequenced (First Base Laboratories, Seri Kembangan,
Malaysia) using SKH2 primer. A homology search was per-
formed using Basic Local Allignment Search Tool (BLAST)
(http://www.ncbi.nlm.nih.gov/blast). The PspA clades
were analyzed by comparing the homology nucleotide
sequences found from isolates in this study with those
sequences of the clade-defining region of invasive refer-
ences sequences retrieved from GenBank.13
Data interpretation
Data analysis such as serotype distribution, antimicrobial
susceptibility pattern, and other variables were performed
by SPSS software (IBM SPSS, New York USA). Differences in
proportion were compared using the Chi-square test of
independence and Fisher exact test. A p value< 0.050 was
considered statistically significant.Annealing temperature Reference
A 55 C 21
C
53 C 22
TGGTT 62 C (13,14)
TGGTT 62 C (13,14)
62 C (12,14)
TGGTT 58 C (12,13)
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Of the 210 children attending the three day care centers,
only 195 were included in the study (response rate was
93%). Of these, 108 (55.4%) were boys and 87 (44.6%) were
girls. A total of 69 strains (35.4%) of pneumococci were
isolated from the nasal swabs of 195 healthy children. Of
these, 67 strains showed 11 different serotypes and 2
strains (2.9%) were nontypeable (Table 2). The top six
serotypes were 6A, 23F, 19A, 6B, 19F, and 15C, constituting
87% of all strains. Also, 40.6% of the serotypes are found in
PCV7 and PCV10 and the coverage rates increased to 69.5%
if PCV13 is taken into account.
Among the 69 isolates, 16 (23.2%) were penicillin-
resistant S pneumoniae (PRSP), 5 (5.8%) were penicillin-
intermediate S pneumoniae (PISP), and 48 (69.6%) were
penicillin-susceptible S pneumoniae (PSSP). For erythro-
mycin, 23 strains (33.3%) were resistant and 46 (66.7%)
were susceptible. Resistance to co-trimoxazole was 31.9%,
whereas 62.3% were susceptible. All PRSPs were resistant to
erythromycin and 14 PRSPs (87.5%) were resistant to co-
trimoxazole. Overall, 14 strains (20.3%) were MDRSP by
being resistant to more than two classes of antibiotic. The
most common type of PRSPs and MDRSPs was serotype 6A
(14.5%), followed by 23F (4.3%) and nontypeable NT (1.5%).
All pneumococcal isolates were susceptible to amoxicillin/
clavulanic acid, ceftriaxone, and cefotaxime.
All 69 isolates in this study showed amplification in the
PspA family typing. PCR products ranged from 1000 bp for
family 1 and 1200-1400 bp for family 2. Of these, 24.6%
belonged to PspA family 1 (15 isolates clade 1, 2 isolates
clade 2), 71.0% were PspA family 2 (26 isolates clade 3, 10
isolates clade 4, and 13 isolates clade 5) and 4.3% wereTable 2 Antimicrobial susceptibility patterns and serotype dist
day care centers in Kuala Lumpur, Malaysia
Capsular serotypes
Nonsusceptib
P SXT E AMC CTX CRO
6A (29%) d d 1 d d d
23F (18.8%) d 1 d d d d
19A (11.6%) d 1 d d d d
6B (10.1%) d d 1 d - d
19F (8.7%) d 1 1 d d d
15C (8.7%) d d d d d d
11A (2.9%) d d d d d d
18C (2.9%) d d d d d d
23A (1.4%) d d d d d d
23B (1.4%) d d d d d d
20 (1.4%) d d d d d d
Nontypeable(NT) (2.9%) d d d d d d
a Antimicrobial susceptibility pattern was determined by the E-test a
< 0.06 mg/mL: susceptible, MIC of > 0.12 to 1.0 mg/mL: intermedia
< 0.25 mg/mL: susceptible, MIC of 0.5 mg/mL: intermediate and MIC
mL:susceptible; MIC of 1 to 2 mg/mL: intermediate and MIC of > 4 mg/
mL: susceptible; MIC of 4 mg/mL: intermediate and MIC of > 8 mg
< 1.0 mg/mL: susceptible; MIC of 2 mg/mL: intermediate and MIC of >
b No of nonsusceptible (resistant or intermediate) and susceptible s
c Multidrug-resistant strains.family 3 (3 isolates clade 6). With regard to PspA clade
distribution, clade 3 (37.7%) was predominant, followed by
clade 1 (21.7%), clade 5 (18.8%), clade 4 (14.5%), clade 6
(4.3%), and clade 2 (2.9%).
As shown in Table 3, serotype 6A, 23F, 19A, and 6B,
which were predominant isolates, were grouped as either
family 1 or family 2. PspA family 2 was found in serotypes
19F, 15C, 11A, 18C, 23A, and 20 whereas PspA family 1 was
found in serotypes 6A, 23F, 19A, and 6B. Chi-square and
Fisher exact analysis in all possible orientations of the
variables showed no significant correlations except
between PspA family typing and serotypes 23F (p Z 0.028)
and 6B (p Z 0.010), respectively.
PCR detection of pneumolysin (ply) gene and autolysin
(lytA) gene on all strains gave positive results for pneu-
mococci (Figs. 1 and 2) which then was confirmed by
sequencing.
There was no significant difference in PspA family typing
by age group, sex, and penicillin susceptibility (p > 0.050).
There was no significant difference in PspA family typing
by capsular serotypes (p > 0.050) except for serotypes 23F
and 6B (p < 0.050).Discussion
The colonization rate of 35.4% in the current study is higher
than the 10-11% rate reported among children in earlier
studies in Malaysia.23,24 High pneumococcal carriage rates
in children have been recorded in other countries such as
Indonesia (48%),2 Vietnam (44%),25 and Taiwan (41%).26
Pneumococcal carriage can be the main source for hori-
zontal spread of pneumococcal infection within theribution of S pneumoniae among carriage isolates from three
Antimicrobial agenta
le strainb Susceptible strainb
P,E E, SXT P, SXT P,E, SXT c P,E,SXT,AMC,CRO,CTX
1 1 d 10 7
1 d d 3 8
d d d d 7
d 1 d d 4
d 2 d d 2
d d d d 6
d d d d 2
d d d d 2
d d d d 1
d d d d 1
d d d d 1
d d d 1 1
nd interpreted according to CLSI guidelines; penicillin (P)- MIC of
te and MIC of > 2.0 mg/mL: resistant; erythromycin (E)-MIC of
of > 1 mg/mL: resistant; co-trimoxazole (SXT)- MIC of < 0.5 mg/
mL: resistant; amoxicillin/clavulanic acid (AMC)- MIC of < 2.0 mg/
/mL: resistant; cefotaxime (CTX) and ceftriaxone (CRO)-MIC of
4 mg/mL: resistant.
train.
Figure 2. Presence of autolysin gene by amplification of
319 bp lytA gene. The first lane is Molecular Weight Marker (M)
for 100 bp. NC Z negative control; PC Z positive control.
Lanes 4 to 13: S pneumoniae strains 1-10.
Figure 1. Presence of pneumolysin gene by amplification of
348-bp ply gene. First lane is Molecular Weight Marker (M) for
100 bp. NCZ negative control; PCZ positive control. Lanes 4
to 13: S pneumoniae strains 1-10.
184 M.M. Yatim et al.community. In healthy children, risk factors such as
crowding as seen in day care centers may play an important
role in colonization and spread of pneumococcal strains.
Serotype distribution of pneumococcal carriage in this
study showed findings similar to those in other AsianTable 3 Frequency of PspA family typing and PspA clade of S p
Variables Family 1 (
Clade Clade 1
Age < 2 y 3
> 2-5 y 12
Sex Male 7
Female 8
Penicillin susceptibility Susceptible (n Z 48) 13
Nonsusceptible (n Z 21) 2











Nontypeable (2.9%) 0countries.24 Six serotypes (6A, 23F, 19A, 6B, 19F, and 15C)
are dominant (87%). These serotypes are also the cause of
certain diseases in Malaysian children.27 Vaccine coverage
of PCV7 (40.6%), PCV10 (40.6%), and PCV13 (69.5%) among
carriage isolates in this study showed findings almost similar
to those from the study done by Yasin et al27 where among
the invasive isolates in children younger than 2 years, 44%,
56%, and 78% belonged to serotypes included in PCV7,
PCV10, and PCV13, respectively. In Malaysia, PCV7 was
introduced in 2005, followed by PCV10 in 2009 and PCV13 in
2010.27 However, this conjugate vaccine is not given to all
Malaysian children because it is not yet included in the
National Immunisation Program (NIP).
The use of penicillin and other antibiotics had reduced
the mortality and morbidity from pneumococcal infections
worldwide. However, in recent years, S pneumoniae has
demonstrated increasing resistance to commonly used
antibiotics, especially penicillin. These problems are more
frequently found in children than in adults.28 The high rate
of resistance to penicillin and other antimicrobial agents in
S pneumoniae in this study is consistent with that in other
countries in the Asian-Pacific region.24 We also found that
the PRSP rate among carriage strain was higher (23.2%)
when compared with the rate in a previous study done in
Malaysia (13.3%).24 The increased difficulty in treating
pneumococcal infections makes prevention through vacci-
nation even more important.15 Although the currently
licensed PPV23 and PCV7 have proved to be effective, the
immunogenicity is age dependent. Nevertheless, a pneu-
mococcal conjugate vaccine such as PCV7 confers protec-
tion against a limited number of serotypes, and many
developing countries cannot afford to purchase it because
of its cost.
Recent research is focusing on protein-based vaccine
candidates such as PspA. PspA inhibits fixation of comple-
ment C3 on the pneumococcal cell surface, thus protecting
the pneumococcus from clearance by the host complementneumoniae isolates
n Z 17) Family 2 (n Z 49) Family 3 (n Z 3)
Clade 2 Clade 3 Clade 4 Clade 5 Clade 6
0 9 5 3 0
2 17 5 10 3
2 20 6 6 1
0 6 4 7 2
2 10 10 12 1
0 16 0 1 2
0 12 2 2 0
0 4 0 2 0
0 0 0 7 0
2 1 0 1 0
0 4 1 0 1
0 0 5 1 0
0 2 0 0 0
0 2 0 0 0
0 0 1 0 0
0 0 0 0 1
0 1 0 0 0
0 0 1 0 1
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thus providing protection against apolactoferrin, which is
bactericidal against the pneumococcus.19,29 In this study,
all the isolates showed amplification of PspA family typing.
The predominant PspA family 2 among pneumococcal
carriage in this study showed findings similar to those in
other countries such as Brazil, Korea, and Spain.7,30,31
However, the clade distribution of PspA was slightly
different in healthy Brazilian children,7 in whom clade 4
was predominant, followed by clades 1, 3, 2, and 5. In our
study we observed that clade 3 was predominant, followed
by clades 1, 5, 4, 6, and 2.
PspA is said to be cross-protective and has been shown to
protect mice against pneumonia, fatal sepsis, and
carriage.32e35 PspA also has been shown to induce both
systemic and mucosal antibody response against experi-
mental pneumococcal carriage in humans.36,37 Baril et al38
demonstrated that PspA was efficient at eliciting T cell and
humoral immune responses. A study has shown that fusion
proteins containing family 1 and family 2 PspA fragments
can induce broader protection against pneumococcus in
mice.39 In our study, there was no correlation between
PspA families and sex, age, and penicillin susceptibility,
thus making PspA a suitable vaccine candidate. However,
PspA families showed a significant result in relation to some
capsular serotypes as was seen in serotype 23F and 6B.
There was no suitable explanation in this situation. To
obtain more conclusive data, further investigation of PspA
family distribution among nasal carriages and clinical
isolates in this country is required. In this study, 95.7% of
pneumococcal isolates expressed either PspA family 1 or 2.
This finding supports a mixture of PspA family 1 and family 2
could be considered for development of future vaccines. To
our knowledge, this is the first study relating PspA family
types in Malaysia. By studying and exploring the pattern of
distribution based on PspA typing, it would provide useful
information for the suitability of this protein antigen as
a vaccine candidate against pneumococcal population.
Other protein candidates such as pneumolysin, PsaA, CbpA,
neuraminidase, and autolysin have been suggested as
potential candidates, but PspA, PsaA, and ply have been
the leading vaccine candidates.10 Combinations of PspA
with other proteins should be considered in future studies
for better protection (Table 3).Conflict of interest
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